IMR Press / FBL / Volume 23 / Issue 1 / DOI: 10.2741/4585

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease

Show Less
1 Nephrology Section, Veterans Affairs Medical Center, Long Beach, 5901 E 7th St, Long Beach, CA 90822, USA
2 University of California, Irvine, 333 City Blvd West, Orange, CA 92868, USA
Front. Biosci. (Landmark Ed) 2018, 23(1), 146–161;
Published: 1 January 2018

Chronic kidney disease (CKD) is a progressive condition marked by protracted kidney damage which over time can lead to end stage renal disease (ESRD). CKD can be categorized into different stages based on the extent of renal damage and degree of renal dysfunction with ESRD requiring renal replacement therapy considered the final stage. It is important to note that CKD in all of its forms is associated with accelerated atherosclerosis, cardiovascular (CV) disease and poor CV outcomes. While a number of factors contribute to the high risk of CV mortality in this patient population, dyslipidemia is considered to be a key player in the pathogenesis of CV disease in CKD. Molecular mechanisms responsible for CKD-associated lipid disorders are unique and greatly influenced by the stage of renal disease, presence and degree of proteinuria and in patients with ESRD, modality of renal replacement therapy. This article provides a detailed overview of the molecular mechanisms which cause dyslipidemia and the nature of lipid disorders associated with CKD and ESRD.

Chronic kidney disease
End Stage Renal Disease
Lipid Metabolism
Cardiovascular Disease
Back to top